Acta Medica Iranica 2011. 49(11):701-706.

Comparison of the Efficacy of Nifedipine and Hydralazine in Hypertensive Crisis in Pregnancy
Zahra Rezaei, Fatemeh Rahimi Sharbaf, Mino Pourmojieb, Yashar Youefzadeh-Fard, Manijeh Motevalian, Zahra Khazaeipour, Sara Esmaeili


Intravenous hydralazine is a commonly administered arteriolar vasodilator that is effective for hypertensive emergencies associated with pregnancy. Oral nifedipine is an alternative in management of these patients. In this study the efficacy of nifedipine and hydralazine in pregnancy was compared in a group of Iranian patients. Fifty hypertensive pregnant women were enrolled in the study. A randomized clinical trial was performed, in which patients in two groups received intravenus hydralazine or oral nifedipine to achieve target blood pressure reduction. The primary outcomes measured were the time and doses required for desired blood pressure achievement. Secondary measures included urinary output and maternal and neonatal side effects. The time required for reduction in systolic and diastolic blood pressure was shorter for oral nifedipine group (24.0±10.0 min) than intravenus Hydralazine group (34.8±18.8 min) (P≤0.016). Less frequent doses were required with oral nifedipine (1.2±0.5) compared to intravenus hydralazine (2.1±1.0) (P≤0.0005). There were no episodes of hypotension after hydralazine and one after nifedipine. Nifedipine and hydralazine are safe and effective antihypertensive drugs, showing a controlled and comparable blood pressure reduction in women with hypertensive emergencies in pregnancy. Both drugs reduce episodes of persistent severe hypertension. Considering pharmacokinetic properties of nifedipine such as rapid onset and long duration of action, the good oral bioavailability and less frequent side effects, it looks more preferable in hypertension emergencies of pregnancy than hydralazine.


Hydralazine; Hypertensive crisis; Nifedipine; Pre-eclampsia

Full Text:



Rey E, LeLorier J, Burgess E, Lange IR, Leduc L. Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensivedisorders in pregnancy. CMAJ 1997;157(9):1245-54.

Department of Health. Report on Confidential Enquiries into Maternal Deaths in England and Wales 1982-1984. London: HMSO, 1989.

Department of Health. Report on Confidential Enquiries into Maternal Deaths in the United Kingdom 1985-1987. London: HMSO, 1991.

Department of Health. Report on Confidential Enquiries into Maternal Deaths in the United Kingdom 1988-1990. London: HMSO, 1994.

Department of Health. Report on Confidential Enquiries into Maternal Deaths in the United Kingdom 1991-1993. London: HMSO, 1996.

Lewis G, Drife J. Why Mothers Die 1997-1999: The Fifth Report of the Confidential Enquiries into. Maternal Deaths in the United Kingdom. London: RCOG Press,2001.

Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183(1):S1-S22.

Brown MA, Hague WM, Higgins J, Lowe S, McCowanL, Oats J, Peek MJ, Rowan JA, Walters BN; Australasian Society for the Study of Hypertension in Pregnancy. The detection, investigation and management of hypertension in pregnancy: executive summary. Aust N Z J Obstet Gynaecol 2000;40(2):133-8.

Rhoney D, Peacock WF. Intravenous therapy for hypertensive emergencies, part 1. Am J Health Syst Pharm 2009;66(15):1343-52.

Cressman MD, Vidt DG, Gifford RW Jr, Moore WS, Wilson DJ. Intravenous labetalol in the management of severe hypertension and hypertensive emergencies. AmHeart J 1984;107(5 Pt 1):980-5.

Elatrous S, Nouira S, Ouanes Besbes L, Marghli S, Boussarssar M, Sakkouhi M, Abroug F. Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol. Intensive Care Med 2002;28(9):1281-6.

Huey J, Thomas JP, Hendricks DR, Wehmeyer AE, Johns LJ, MacCosbe PE. Clinical evaluation of intravenous labetalol for the treatment of hypertensive urgency. Am J Hypertens 1988;1(3 Pt 3):284S-289S.

Mabie WC, Gonzalez AR, Sibai BM, Amon E. A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol 1987;70(3 Pt 1):328-33.

Morel DR, Forster A, Suter PM. I.v. labetalol in the treatment of hypertension following coronary-artery surgery. Br J Anaesth 1982;54(11):1191-6.

Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003;327(7421):955.

Fenakel K, Fenakel G, Appelman Z, Lurie S, Katz Z, Shoham Z. Nifedipine in the treatment of severe preeclampsia. Obstet Gynecol 1991;77(3):331-7.

Vermillion ST, Scardo JA, Newman RB, Chauhan SP. A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. Am J Obstet Gynecol 1999;181(4):858-61.

Lindow SW, Davies N, Davey DA, Smith JA. The effect of sublingual nifedipine on uteroplacental blood flow in hypertensive pregnancy. Br J Obstet Gynaecol 1988;95(12):1276-81.

Moretti MM, Fairlie FM, Akl S, Khoury AD, Sibai BM. The effect of nifedipine therapy on fetal and placental Doppler waveforms in preeclampsia remote from term. Am J Obstet Gynecol 1990;163(6 Pt 1):1844-8.

Cutler JA. Calcium-channel blockers for hypertension: uncertainty continues. N Engl J Med 1998;338(10):679-81.

Ben-Ami M, Giladi Y, Shalev E. The combination of magnesium sulphate and nifedipine: a cause ofneuromuscular blockade. Br J Obstet Gynaecol 1994;101(3):262-3.

Snyder SW, Cardwell MS. Neuromuscular blockade with magnesium sulfate and nifedipine. Am J Obstet Gynecol 1989;161(1):35-6.

Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek JC, de Mena FT, López JC; or the HYLA treatment study. Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2006;128(1-2):157-62.

Stevens TP, Guillet R. Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy. J Pediatr 1995;127(1):151-3.

Aali BS, Nejad SS. Nifedipine or hydralazine as a firstline agent to control hypertension in severe preeclampsia. Acta Obstet Gynecol Scand 2002;81(1):25-30.

Kwawukume EY, Ghosh TS. Oral nifedipine therapy in the management of severe preeclampsia. Int J Gynaecol Obstet 1995;49(3):265-9.

Papatsonis DN, Lok CA, Bos JM, Geijn HP, Dekker GA. Calcium channel blockers in the management of preterm labor and hypertension in pregnancy. Eur J Obstet Gynecol Reprod Biol 2001;97(2):122-40.

Borghi C, Esposti DD, Cassani A, Immordino V, Bovicelli L, Ambrosioni E. The treatment of hypertension in pregnancy. J Hypertens Suppl 2002;20(2):S52-6.

Magee LA, Miremadi S, Li J, Cheng C, Ensom MH, Carleton B, Côté AM, von Dadelszen P. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol 2005;193(1):153-63.

Magee LA, von Dadelszen P. The management of severe hypertension. Semin Perinatol 2009;33(3):138-42.

Podymow T, August P. Hypertension in pregnancy. Adv Chronic Kidney Dis 2007;14(2):178-90.

Podymow T, August P. Antihypertensive drugs in pregnancy. Semin Nephrol 2011;31(1):70-85.

Montán S. Drugs used in hypertensive diseases in pregnancy. Curr Opin Obstet Gynecol 2004;16(2):111-5.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.